--------------------------
OMB APPROVAL
--------------------------
OMB Number: 3235-0362
Expires:September 30, 1998
Estimated average burden
hours per response ....1.0
FORM 5
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934, Section 17(a) of the
Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
[ ] Check box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).
[ ] Form 3 Holdings Reported
[X] Form 4 Transactions Reported
===================================================================
1. Name and Address of Reporting Person*
Novartis AG
- -------------------------------------------------------------------
(Last) (First) (Middle)
Schwarzwaldallee 215
- -------------------------------------------------------------------
(Street)
CH-4002, Basel
- -------------------------------------------------------------------
(City) (State) (Zip)
Switzerland
===================================================================
2. Issuer Name and Ticker or Trading Symbol
Chiron Corporation / CHIR
======================================================================
3. IRS or Social Security Number of Reporting Person (Voluntary)
======================================================================
4. Statement for Month/Year
1997
======================================================================
5. If Amendment, Date of Original (Month/Year)
======================================================================
6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
[ ] Director [X ] 10% Owner
[ ] Officer (give title below) [ ] Other (specify below)
-----------------------------------------------------------
======================================================================
7. Individual or Joint/Group Reporting
(Check applicable box)
[ ] Form Filed by One Reporting Person
[ X ] Form Filed by More than One Reporting Person
======================================================================
<PAGE>
Table 1 -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned
======================================================================
<TABLE>
<CAPTION>
4.
Securities 5.
Acquired Amount of
(A) or (D) Securities 6. 7.
Disposed of (D) Beneficially Ownership Nature of
1. 2. 3. (Instr. 3, 4 and 5) Owned at Form: Indirect
Title of Transaction Transaction -------------------------- end of Issuer's Direct (D) Beneficial
Security Date Code (A) or Fiscal Year or Indirect (I) Ownership
(Instr. 3) (mm/dd/yy) (Instr. 8) Amount (D) Price (Instr. 3 and 4) (Instr. 4) (Instr. 4)
- ----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Common Stock+ 5,121,460 I Through
Novartis
Pharma AG
- ----------------------------------------------------------------------------------------------------------------------------------
Common Stock+ 73,842,852 I Through
Novartis
Biotech
- ----------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
Common Stock+ 7,456 I Through
Novartis
Corporation
- ----------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
==================================================================================================================================
</TABLE>
* If the form is filed by more than one reporting person,
see Instruction 4(b)(v)
Page 1 of 4
<PAGE>
FORM 5 (continued)
Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
=====================================================================
<TABLE>
<CAPTION>
9.
5. Number 10.
2. Number 7. of Owner- 11.
Conver- of Deriva- 6. Title 8. Deriva- ship of Nature
1. sion tive Date and Price tive Se- Deriva- of
Title or Securities Exercis- Amount of curities tive Se- Indi-
of Exer- 3. Acquired able and of De- Bene- curity: rect
Deriva- cise Trans- 4. (A) or Expira- Under- riva- ficially Direct Bene-
tive Price action Trans- Disposed tion lying tive Owned (D) or ficial
Secu- of Date action of (D) Date Securi- Secu- at End Indirect Owner-
rity Deriva- (Month/ Code (Instr. 3, (Month/ ties rity of Year (I) ship
(Instr. tive Day/ (Instr. 4 and Day/ (Instr. (Instr. (Instr. (Instr. (Instr.
3) Security Year) 4) 5) Year) 3 and 4 4) 4) 4) 4)
- ----------------------------------------------------------------------------------------------------------------------------------
Amount
or
Date Expira- Number
Exer- tion of
(A) (D) cisable Date Title Shares
- ----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Put
Options++ $30 2/25/97 4S 6,000,000 3/25/2000 3/25/2000 Common 6,000,000 $7.17 6,000,000-
- ----------------------------------------------------------------------------------------------------------------------------------
7-1/4% $47 Anytime 7/1/2015 Common 348,028 $10,069,000 D
Conver-
tible
Sub-
ordinated
Debentures
due 2015+
- ----------------------------------------------------------------------------------------------------------------------------------
===================================================================================================================================
Explanation of Responses:
+Novartis AG is the beneficial owner of a total of 79,318,836 Common Shares of Chiron Corporation.
Of such shares, 5,121,460 shares are owned by Novartis Pharma AG (a wholly owned subsidiary of
Novartis AG) 73,842,852 shares are owned by Novartis Biotech Partnership, Inc. (a wholly owned
subsidiary of Novartis AG) 7,456 shares are owned by Novartis Corporation (a wholly owned subsidiary
of Novartis AG) and 348,028 shares represent shares obtainable on the conversion of 7-1/4%
Convertible Subordinated Debentures due 2015 of Chiron Corporation owned by Novartis AG. ++On
February 25, 1997, Novartis Biotech (BVI) Limited ("NBBL"), a wholly owned subsidiary of Novartis
AG, sold 6,000,000 "European" style put options for aggregate consideration of $43,000,000. Each
option entitles the holder thereof on the maturity date to receive from NBBL an amount equal to the
excess, if any, of $30 over the per share price of Chiron Common Stock.
</TABLE>
** INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACTS CONSTITUTE
FEDERAL CRIMINAL VIOLATIONS.
SEE 18 U.S.C. 1001 AND U.S.C. 78FF(A).
NOTE: File three copies of this Form, one of which must be manually
signed. If space provided is insufficient, see Instruction 6 for
procedure.
/s/ John Manser/Jurgen Vierkotten 2/17/98
- ----------------------------------- -------------------------
**Signature of Reporting Person Date
Potential persons who are to respond to the collection of information contained
in this form are not required to respond unless the form displays a currently
valid OMB number.
Page 2 of 4
<PAGE>
Additional Reporting Persons
Additional Reporting Person: Novartis Biotech (BVI) Limited
(a wholly owned subsidiary of
Novartis AG)
Address: 560 Morris Avenue; Summit, NJ 07901
Designated Filer: Novartis AG
Issuer & Ticker Symbol: Chiron Corporation / CHIR
Statement for Month/Year: 1997
/s/ Jeff Benjamin 2/17/98
------------------------- --------------
Signature of Date
Reporting Person
Additional Reporting Person: Novartis Pharma AG
(a wholly owned subsidiary of
Novartis AG)
Address: Schwarzwaldallee 215; CH-4002
Basel, Switzerland
Designated Filer: Novartis AG
Issuer & Ticker Symbol: Chiron Corporation / CHIR
Statement for Month/Year: 1997
/s/ Herbert Gut/J. Mamie 2/17/98
------------------------- --------------
Signature of Date
Reporting Person
Additional Reporting Person: Novartis Biotech Partnership, Inc.
(a wholly owned subsidiary of
Novartis AG)
Address: 560 Morris Avenue;
Summit, NJ 07901
Designated Filer: Novartis AG
Issuer & Ticker Symbol: Chiron Corporation / CHIR
Statement for Month/Year: 1997
/s/ Jeff Benjamin 2/17/98
------------------------- --------------
Signature of Date
Reporting Person
Page 3 of 4
<PAGE>
Additional Reporting Person: Novartis Corporation
(a wholly owned subsidiary of
Novartis AG)
Address: 560 Morris Avenue;
Summit, NJ 07901
Designated Filer: Novartis AG
Issuer & Ticker Symbol: Chiron Corporation / CHIR
Statement for Month/Year: 1997
/s/ Jeff Benjamin 2/17/98
------------------------- --------------
Signature of Date
Reporting Person
Page 4 of 4
